As of Nov 19, 2026, 1 of 2 active firms rate ENLV a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ENLV EPS & revenue forecast
EPS · NEXT QUARTER
$-4.16
Range $-4.16 – $-4.16 · 1 analysts · -100% YoY
Next period, 1 analysts expect Enlivex Therapeutics Ltd to earn $-4.16 a share (range $-4.16 – $-4.16), versus $6189.60 a year earlier. Full-year consensus is $-18.40, growing to $-3.36 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Enlivex Therapeutics Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ENLV.
#1
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$80.00+6566.7% to target
Overall win rate
36%
+ Follow
#2
Jason Kolbert
D. Boral Capital · Rank #562
Neutral
No targeton ENLV
Overall win rate
22%
+ Follow
#3
RS
Ram Selvaraju
H.C. Wainwright
Buy
$80.00+6566.7% to target
Coverage
—
+ Follow
ENLV stock forecast FAQ
What is ENLV's average 12-month price target?+
The 1 active firms with a live target average $80.00 for Enlivex Therapeutics Ltd over the next 12 months, ranging from a $80.00 high to a $80.00 low, as of Nov 19, 2026.
Is ENLV stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover ENLV?+
2 active firms have a recognized rating on Enlivex Therapeutics Ltd as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ENLV?+
Among analysts who currently cover ENLV, Raghuram Selvaraju of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #423). Their current call is Buy with a $80.00 target.
What is Enlivex Therapeutics Ltd's projected EPS for next quarter?+
The consensus estimate is $-4.16 per share (range $-4.16 – $-4.16) across 1 analysts. Full-year EPS is projected at $-18.40, rising to $-3.36 the following year.
How much revenue is Enlivex Therapeutics Ltd expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ENLV lately?+
As of Nov 19, 2026, 1 of 2 active firms rate ENLV a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ENLV calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.